Comparative Pharmacology
Head-to-head clinical analysis: CLONAZEPAM versus HALCION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLONAZEPAM versus HALCION.
CLONAZEPAM vs HALCION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhances GABA-A receptor inhibitory neurotransmission by binding to benzodiazepine binding site, increasing frequency of chloride channel opening, leading to neuronal hyperpolarization.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
0.5 mg orally three times daily; maximum 20 mg/day
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
None Documented
None Documented
Terminal elimination half-life: 19-60 hours (mean 30-40 hours); clinical context: long-acting benzodiazepine, allows once or twice daily dosing; accumulation occurs with repeated use.
Clinical Note
moderateClonazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Fluconazole
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Renal: 50-70% as metabolites (mostly glucuronide conjugates), <2% unchanged; fecal: 10-20%; biliary: minor.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Fluconazole can be decreased when combined with Clonazepam."